LAB - Standard BioTools Inc.
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. About Standard BioTools Inc.
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts
BALA CYNWYD, Pa. , June 19, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.
SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard BioTools shareholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 o.
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrador Gold Corp. (TSXV: LAB) ("LabGold") has announced plans for its 2026 exploration programs for the Company's Mariposa and Eureka Dome gold projects in the White Gold District, Yukon.
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prolific White Gold District, historical exploration results, the recently approved Class 1 permit, planned 2026 exploration activities and upcoming catalysts as the Company advances this district-scale gold opportunity.
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates
Standard BioTools (LAB) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.
Standard BioTools (NASDAQ: LAB - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 53.7% of Standard BioTools
BOSTON, Mass. , April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U. S. market close.
Standard BioTools (NASDAQ: LAB - Get Free Report) and PPJ Enterprise (OTCMKTS:PPJE - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership. Volatility and Risk Standard BioTools has a
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.
Standard BioTools (NASDAQ: LAB - Get Free Report) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $18.50 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page